Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Liraglutide - Novo Nordisk

X
Drug Profile

Liraglutide - Novo Nordisk

Alternative Names: LATIN T1D; Liraglutide; NN 2211; NN 9211; NN-8022; NNC 90-1170; Saxenda; Victoza

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Novo Nordisk
  • Developer Novo Nordisk; University of North Carolina at Chapel Hill
  • Class Anti-inflammatories; Antihyperglycaemics; Antiparkinsonians; Antirheumatics; Glucagon-like peptides; Obesity therapies
  • Mechanism of Action Glucagon like peptide 1 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Obesity; Type 2 diabetes mellitus
  • Phase II Parkinson's disease; Pouchitis; Smoking withdrawal
  • Discontinued Type 1 diabetes mellitus

Most Recent Events

  • 31 Dec 2022 Novo Nordisk has patent protection for liraglutide in USA and European Union till 2023
  • 03 Aug 2022 Novo Nordisk in collaboration with Cedars-Sinai Medical Center completes a phase II trial in Parkinson disease (Treatment-experienced) (SC) in USA (NCT02953665) (U1111-1173-0106)
  • 25 May 2022 Novo Nordisk completes a phase II trial in Smoking withdrawal in USA (Injection) (NCT03712098)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top